Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1G | O43497 | 1/20 | 0.49 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.49 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.49 |
| ▸ | TACR1 | P25103 | 12/20 | 0.46 |
| ▸ | MRGPRX4 | Q96LA9 | 4/20 | 0.44 |
| ▸ | CETP | P11597 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2935441 | 0.89 | CACNA1G (0.55) | CACNA1GCACNA1BCACNA1CTACR1CETP | |
| SCHEMBL29746466 | 0.84 | CACNA1G (0.51) | CACNA1GCACNA1BCACNA1CTACR1CETP | |
| SCHEMBL13818149 | 0.84 | CACNA1G (0.51) | CACNA1GCACNA1BCACNA1CTACR1CETP | |
| SCHEMBL545966 | 0.83 | CACNA1G (0.50) | CACNA1GCACNA1BCACNA1CTACR1CETP | |
| SCHEMBL346774 | 0.81 | MRGPRX4 (0.48) | TACR1MRGPRX4SERPINE1 | |
| SCHEMBL12481999 | 0.81 | TACR1 (0.44) | CACNA1GCACNA1BCACNA1CTACR1MRGPRX4 | |
| SCHEMBL6121602 | 0.79 | MRGPRX4 (0.47) | TACR1MRGPRX4SERPINE1 | |
| Hydrochloric Acid SCHEMBL345549 | 0.79 | MRGPRX4 (0.47) | TACR1MRGPRX4SERPINE1 | |
| SCHEMBL4830438 | 0.77 | MEN1 (0.49) | MRGPRX4MEN1KMT2A | |
| SCHEMBL1243793 | 0.76 | HDAC1 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150112071-A1 | PREPARATION OF AMINOTETRALIN COMPOUNDS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-04-23 | — | — | US | disclosed |
| US-20140256947-A1 | PREPARATION OF AMINOTETRALIN COMPOUNDS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-09-11 | — | — | US | disclosed |
| US-20100197924-A1 | PREPARATION OF AMINOTETRALIN COMPOUNDS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-08-05 | — | — | US | disclosed |
| US-20100197924-A1 | PREPARATION OF AMINOTETRALIN COMPOUNDS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197924-A1 | PREPARATION OF AMINOTETRALIN COMPOUNDS | MAP4K5, MAP4K2, MAP4K1 | CACNA1G 3195/4885CACNA1B 2839/4885CACNA1C 3632/4885 |
| US-20140256947-A1 | PREPARATION OF AMINOTETRALIN COMPOUNDS | MAP4K5, MAP4K2, MAP4K1 | CACNA1G 3195/4885CACNA1B 2839/4885CACNA1C 3632/4885 |
| US-20150112071-A1 | PREPARATION OF AMINOTETRALIN COMPOUNDS | MAP4K5, MAP4K2, MAP4K1 | CACNA1G 3195/4885CACNA1B 2839/4885CACNA1C 3632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.